A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions
- 1 November 1994
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 38 (11) , 2557-2563
- https://doi.org/10.1128/aac.38.11.2557
Abstract
Even though the macrophage is the host cell for the intracellular bacterial parasite Mycobacterium avium, macrophages have undergone only limited evaluation as models for determining the capacities of antimycobacterial drugs to inhibit the growth of M. avium within this relevant intracellular environment. In the present study, we demonstrated that a panel of M. avium isolates could actively infect homogeneous monolayers of murine bone marrow-derived macrophages. A number of established and experimental antimycobacterial drugs were then added to these cultures at a range of concentrations, and their effects on the numbers of surviving bacilli were determined 8 days later. By plotting such numbers versus drug concentrations it was then possible to clearly distinguish between compounds with bactericidal activity (such as rifabutin and PD 125354) and those with bacteriostatic effects (such as clarithromycin), even though several of these compounds had very similar MICs. In addition, an estimate of the potential therapeutic efficiency of each drug could be made by determining the concentration needed to destroy an arbitrary percentage of the inoculum (in this case, the bactericidal concentration destroying 99% of the inoculum). Such values were considerably in excess of the MICs and may more realistically reflect the concentrations in serum required to effectively reduce the bacterial burden in vivo.Keywords
This publication has 40 references indexed in Scilit:
- Clinical trials in Mycobacterium avium therapy: lessons to take homeResearch in Microbiology, 1994
- Lack of Acidification in Mycobacterium Phagosomes Produced by Exclusion of the Vesicular Proton-ATPaseScience, 1994
- Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium Complex Disease in Patients Infected with the Human Immunodeficiency VirusNew England Journal of Medicine, 1993
- Two Controlled Trials of Rifabutin Prophylaxis against Mycobacterium avium Complex Infection in AIDSNew England Journal of Medicine, 1993
- Mycobacterium avium Complex Infection and AIDS: Advances in Theory and PracticeClinical Infectious Diseases, 1993
- Mycobacterium avium Infection and AIDS: A Therapeutic Dilemma in Rapid EvolutionThe Journal of Infectious Diseases, 1991
- Strain- and Donor-Related Differences in the Interaction of Mycobacterium avium with Human Monocytes and its Modulation by Interferon-The Journal of Infectious Diseases, 1990
- Comparative in vitro and in vivo activity of rifabutin and rifampicin against mycobacterium avium complexTubercle, 1988
- Mycobacterium avium Complex InfectionThe Journal of Infectious Diseases, 1988
- Basis for Lack of Drug Susceptibility of Atypical MycobacteriaClinical Infectious Diseases, 1981